Postoperative serum α-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma

Oncology Reports

Volumn 24, Issue 2, 2010, Pages 521-528

  Nobuoka, Daisuke ^a   Kato, Yuichiro ^a   Gotohda, Naoto ^a   Takahashi, Shinichiro ^a   Nakagohri, Toshio ^a   Konishi, Masaru ^a   Kinoshita, Taira ^a   Nakatsura, Tetsuya ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

fetoprotein; Des carboxy prothrombin; Hepatectomy; Hepatocellular carcinoma recurrence; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; BLOOD; CARCINOMA, HEPATOCELLULAR; EVALUATION STUDY; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RECURRENT DISEASE; REHABILITATION;

AGED; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 77954359823     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000888     Document Type: Article

References (41)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. McGlynn KA, Tsao L, Hsing AW, Devesa SS and Fraumeni JF Jr: International trends and patterns of primary liver cancer. Int J Cancer 94: 290-296, 2001.
3. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
4. El-Serag HB: Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 37 (Suppl. 2): S88-S94, 2007.
5. Ishii H, Yamamoto J and Ikari T: Adjuvant treatments for resectable hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 15: 459-462, 2008.
6. Kudo M: Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 75 (Suppl. 1): S1-S12, 2008.
7. Nomura F, Ohnishi K and Tanabe Y: Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 64: 1700-1707, 1989.
8. Shimada M, Takenaka K, Fujiwara Y, et al: Des-gammacarboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 78: 2094-2100, 1996.
9. Toyoda H, Kumada T, Osaki Y, et al: Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 4: 1528-1536, 2006.
10. Carr BI, Kanke F, Wise M and Satomura S: Clinical evaluation of Lens culinaris agglutinin-reactive alpha-fetoprotein and desgamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 52: 776-782, 2007.
11. Cucchetti A, Piscaglia F, Caturelli E, et al: Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 16: 413-422, 2009.
12. Honda H, Ochiai K, Adachi E, et al: Hepatocellular carcinoma: correlation of CT, angiographic and histopathologic findings. Radiology 189: 857-862, 1993.
13. Takigawa Y, Sugawara Y, Yamamoto J, et al: New lesions detected by intraoperative ultrasound during liver resection for hepatocellular carcinoma. Ultrasound Med Biol 27: 151-156, 2001. (Pubitemid 32318311)
14. Sobin LH and Wittekind CH: UICC: TNM classification of malignant tumors. 6th edition. Wiley-Liss, New York, 2002.
15. Fujiyama S, Izuno K, Gohshi K, Shibata J and Sato T: Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci 36: 1787-1792, 1991.
16. Sherman M: Surveillance for hepatocellular carcinoma. Semin Oncol 28: 450-459, 2001.
17. Izuno K, Fujiyama S, Yamasaki K, Sato M and Sato T: Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology 42: 387-393, 1995.
18. Toyoda H, Kumada T, Kiriyama S, et al: Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 4: 111-117, 2006.
19. Makuuchi M, Kokudo N, Arii S, et al: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 38: 37-51, 2008.
20. Nakamura S, Nouso K, Sakaguchi K, et al: Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 101: 2038-2043, 2006.
21. Kew M: Alpha-fetoprotein in primary liver cancer and other diseases. Gut 15: 814-821, 1974.
22. Bloomer JR, Waldmann TA, McIntire KR and Klatskin G: Alpha-fetoprotein in non-neoplastic hepatic disorders. JAMA 233: 38-41, 1975.
23. Alpert E and Feller ER: Alpha-fetoprotein (AFP) in benign liver disease. Evidence that normal liver regeneration does not induce AFP synthesis. Gastroenterology 74: 856-858, 1978.
24. Bayati N, Silverman AL and Gordon SC: Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 93: 2452-2456, 1998.
25. Okuda K, Tanaka M, Kanazawa N, et al: Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein. Int J Oncol 14: 265-271, 1999.
26. Hayashi K, Kumada T, Nakano S, et al: Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 94: 3028-3033, 1999.
27. Tateishi R, Shiina S, Yoshida H, et al: Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 44: 1518-1527, 2006.
28. Nakatsura T, Yoshitake Y, Senju S, et al: Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306: 16-25, 2003.
29. Nakatsura T and Nishimura Y: Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 19: 71-77, 2005. (Pubitemid 40559473)
30. Shirakawa H, Kuronuma T, Nishimura Y, et al: Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 34: 649-656, 2009.
31. Hayashi E, Motomura Y, Shirakawa H, et al: Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis. Oncol Rep 22: 149-154, 2009.
32. Tarao K, Takemiya S, Tamai S, et al: Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 79: 688-694, 1997.
33. Goldstein NS, Blue DE, Hankin R, et al: Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Am J Clin Pathol 111: 811-816, 1999. (Pubitemid 29250112)
34. Nakashima O and Kojiro M: Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg 8: 404-409, 2001. (Pubitemid 33725570)
35. Imamura H, Matsuyama Y, Tanaka E, et al: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38: 200-207, 2003.
36. Choi GH, Kim DH, Kang CM, et al: Prognostic factors and optimal treatment strategy for intrahepatic nodular recurrence after curative resection of hepatocellular carcinoma. Ann Surg Oncol 15: 618-629, 2008.
37. Nakatsura T, Komori H, Kubo T, et al: Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 10: 8630-8640, 2004.
38. Motomura Y, Senju S, Nakatsura T, et al: Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res 66: 2414-2422, 2006.
39. Komori H, Nakatsura T, Senju S, et al: Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12: 2689-2697, 2006.
40. Motomura Y, Ikuta Y, Kuronuma T, et al: HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induce specific CTLs: preclinical study using mice. Int J Oncol 32: 985-990, 2008.
41. Shirakawa H, Suzuki H, Shimomura M, et al: Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 100: 1403-1407, 2009.